Clinical trials: Carcinoma, Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer
To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.
- Trial name
- NCT00190710
- Testing
- Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Eli Lilly and Company
Metastatic Nonsmall Cell Lung Cancer
Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer
The study aims include: Exploring potential predictive molecular profiles to immunotherapy/chemotherapy Investigating the role of circulating tumor DNA as a dynamic biomarker during immunotherapy/chemotherapy Identifying possible…
- Trial name
- NCT03512847
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Lung Cancer, Radiotherapy
Radiation Pneumonitis After SBRT for NSCLC
Aims: 1. Evaluate changes in lung function before and after radiotherapy for patients with NSCLC in stage I-III receiving curatively intended radiotherapy 2.
- Conditions
- Lung Cancer, Radiotherapy, Lung Function Changes
- Trial name
- NCT02428049
- Testing
- Stereotactic or conventional radiotherapy and chemotherapy in curative intent
- Where
- Norway
- Volunteers
- 105 people
- Sponsor
- Sykehuset i Vestfold HF
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT04878952
- Testing
- Garmin Vivofit Activity Tracker
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- NRG Oncology
Non Small Cell Lung Cancer
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior…
- Trial name
- NCT05457049
- Testing
- Molecular residual disease test
- Where
- 5 sites in China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer (NSCLC)
A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC
This is a randomized, multicenter, phase III clinical study to compare the efficacy and safety of perioperative treatment with adebrelimab plus platinum-based chemotherapy versus adebrelimab adjuvant therapy in patients with…
- Trial name
- NCT07895238
- Testing
- Adebrelimab (SHR-1316) + chemotherapy, Adebrelimab
- Volunteers
- 1,088 people
- Sponsor
- West China Hospital
Refractory Malignant Solid Neoplasm, Osteosarcoma
AOH1996 for the Treatment of Refractory Solid Tumors
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory).
- Conditions
- Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas
- Trial name
- NCT05227326
- Testing
- PCNA Inhibitor AOH1996
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- City of Hope Medical Center
Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT00516685)
- Testing
- Recombinant Human rEGF-P64K/Montanide Vaccine
- Where
- 10 sites in Malaysia
- Volunteers
- 230 people
- Sponsor
- Bioven Sdn. Bhd.
Mesothelioma, Pancreatic Cancer
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non…
- Conditions
- Mesothelioma, Pancreatic Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT01521325
- Testing
- Amatuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Morphotek
Non Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged…
- Trial name
- NCT00399789
- Testing
- Perifosine
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- AEterna Zentaris
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3).
- Trial name
- NCT05879978
- Testing
- Obrixtamig, Ezabenlimab
- Where
- 8 sites in Belgium, France and 2 more
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer
Phase 1 - open label, multi-center, non-randomized, safety, pharmacokinetic and pharmacodynamics dose escalation study of PF-06459988 as a single agent in patients with advance EGFRm NSCLC (del 19, L858R, +/- T790M).
- Trial name
- NCT02297425
- Testing
- PF-06459988
- Sponsor
- Pfizer
Lung Neoplasms
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
The purpose of this study is to help answer: Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical…
- Trial name
- NCT00356525
- Testing
- pemetrexed, gemcitabine, carboplatin
- Where
- 17 sites in United States, Brazil and 1 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.
- Trial name
- NCT01820091
- Testing
- Folotyn, Fusilev
- Sponsor
- Acrotech Biopharma Inc.
Squamous Cell Non-small Cell Lung Cancer
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after…
- Trial name
- NCT01721759
- Testing
- Nivolumab
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Non-squamous Non-small Cell Lung Cancer
Phase I Study of the Combination of Anlotinib With Gefitinib
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Gefitinib in First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer , to provide…
- Trial name
- NCT03602027
- Testing
- Anlotinib, Gefitinib
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Lung Cancer
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00073866
- Testing
- celecoxib, docetaxel, irinotecan hydrochloride
- Where
- 3 sites in United States
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.